[{"from": "human", "value": "Provide a description of this molecule. [C][C@@H1][C@@H1][C][C@][Branch2][Branch2][#Branch1][C@@H1][Branch2][#Branch1][P][/C][=C][/C][=C][Branch2][#Branch1][=Branch2][/C][C][=C][C][=Branch1][=N][=C][Branch1][=Branch2][C][=Branch1][Ring2][=C][Ring1][=Branch1][O][C][Cl][N][Branch2][=Branch1][C][C][=Branch1][C][=O][C][C@@H1][Branch1][N][C@][Branch1][Branch2][C@H1][Ring2][Ring1][#Branch2][O][Ring1][Ring1][C][O][C][=Branch1][C][=O][C@H1][Branch1][C][C][N][Branch1][C][C][C][=Branch1][C][=O][C][C][C][Branch1][C][C][Branch1][C][C][S][S][C][C][C][Branch1][=Branch1][C][=Branch1][C][=O][N][S][=Branch1][C][=O][=Branch1][C][=O][O][C][\\C][O][C][Branch1][#Branch2][N][C][=Branch1][C][=O][O][Ring2][Branch1][=N][O]"}, {"from": "gpt", "value": "The molecule is an immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells."}]